Kristin Yarema, Ph.D. Chief Executive Officer and Interim Principal Financial Officer

Dr. Yarema brings over two decades of leadership experience in therapeutics. Her most recent role was Chief Executive Officer and Director of Poseida Therapeutics, which was acquired by Roche in January 2025, and she stayed to guide the transition. She previously served as President, Cell Therapy at Poseida and Chief Commercial Officer at Atara Biotherapeutics. Dr. Yarema also held various senior positions at Amgen, including Vice President and Therapeutic Area Head roles in inflammation, as well as commercial leadership. Earlier in her career, she held clinical development, portfolio, and global commercial leadership roles at Novartis and was an Associate Principal at McKinsey & Company.

Dr. Ben Porter-Brown Chief Medical Officer

Dr. Porter-Brown was appointed Chief Medical Officer effective February 16, 2026, bringing over 20 years of clinical development experience in autoimmune and inflammatory diseases. He previously served as Chief Medical Officer at MoonLake Immunotherapeutics. Prior to that, he led the development of amlitelimab, an anti-OX40 ligand monoclonal antibody, at Kymab, Ltd (now part of Sanofi) and held various leadership positions at Roche Pharmaceuticals for 16 years.

Kurinji Pandiyan, Ph.D. Chief Strategy and Operations Officer

Dr. Pandiyan joined ImageneBio in September 2025. She previously served as Head of Portfolio & Strategy and Chief of Staff to the CEO at Poseida Therapeutics, where she also led autoimmune disease development planning. Her past experience includes leadership roles at Atara Biotherapeutics and AVITA Medical, as well as a principal role at Boston Consulting Group (BCG).

Renuka Sivendran, Ph.D. Chief Technical Officer

Dr. Sivendran joined ImageneBio in September 2025. She previously led all CMC (Chemistry, Manufacturing, and Controls) functions as Vice President of Technical Operations at Agenus, Inc. from January 2021. Her background also includes leadership positions at Five Prime Therapeutics (acquired by Amgen), Amgen, and Regeneron.

• Successful Clinical Development and Regulatory Approval of IMG-007: The most significant driver of future revenue growth hinges on the successful completion of clinical trials for IMG-007, particularly the ongoing Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis (AD). Topline data from this trial is anticipated in 2027. Positive results and subsequent regulatory approval would pave the way for commercialization, generating substantial revenue for the company.
• Expansion of IMG-007 to Additional Therapeutic Indications: ImageneBio is developing IMG-007 as a treatment for a range of immunological, autoimmune, and inflammatory conditions. Beyond atopic dermatitis, IMG-007 has completed Phase 1b/2a clinical trials for alopecia areata. Successfully expanding the use of IMG-007 to other dermatology and inflammatory conditions could significantly broaden its market reach and revenue potential.
• Differentiated Profile and Patient Adoption of IMG-007: IMG-007 is highlighted as a receptor-targeting, non-depleting anti-OX40 monoclonal antibody with a differentiated clinical profile and multiple distinguishing features. Notably, it aims to avoid the severe T cell depletion associated with other ADCC-enhanced anti-OX40 antibodies. If these differentiating features translate into a superior safety, efficacy, or dosing profile (such as an approximately five-week half-life supporting less frequent dosing), it could lead to strong market adoption and drive revenue once approved.